eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
1/2018
vol. 22
 
Share:
Share:
more
 
 
abstract:
Review paper

Electrochemotherapy in the treatment of melanoma

Mateusz Wichtowski, Dawid Murawa

Contemp Oncol (Pozn) 2018; 22 (1): 8-13
Online publish date: 2018/04/03
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Electrochemotherapy is a new therapeutic option for patients with locally spread melanoma. It is based on the phenomenon of reversible electroporation, i.e. a transient increase in permeability of cell membranes under the influence of an appropriately modulated electric field. This allows multiplication of toxicity of a cytostatic agent entering the tumour cell. It is highly effective, especially in the palliative treatment of cancers located in the integument of the human body (skin and subcutaneous tissue). Available literature provides a mandate both for the application of this method in the aforementioned cases as well as for further work on its development.

This paper focuses on reviewing the literature concerning the use of electrochemotherapy in the treatment of melanoma.
keywords:

electrochemotherapy, mel-anoma, bleomycin

references:
Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, Garbe C. Metastatic pathways and time courses in the orderly progression of cutaneous melanoma. Br J Dermatol 2002; 147: 62-70.
Eapen S, Dutcher JP. A review of evidence-based treatment of stage IIB to stage IV melanoma. Cancer Invest 2005; 23: 323-37.
Bonenkamp JJ, Thompson JF, de Wilt JH, Doubrovsky A, de Faria Lima R, Kam PC. Isolated limb infusion with fotemustine after dacarbazine chemosensitisation for inoperable loco-regional melanoma recurrence. Eur J Surg Oncol 2004; 30: 1107-12.
Lindner P, Doubrovsky A, Kam P, Thompson JF. Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127-36.
McKay AJ, Byrne DS. Other treatments. In: Textbook of Melanoma. Thompson JF, Morton DL, Kroon BBR (eds.). Martin Dunitz, London 2004; 438-44.
Stevens G, Thompson JF, Firth I, O’Brien CJ, McCarthy WH, Quinn MJ. Locally advanced melanoma: results of postoperative hypofractionated radiation therapy. Cancer 2000; 88: 88-94.
Hersey P, Coates AS, McCarthy WH, et al. Adjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trial. J Clin Oncol 2002; 20: 4181-90.
Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 1484-91.
Marty M, Sersa G, Garbay JR, et al. Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. EJC Suppl 2006; 4: 3-13.
Gehl J, Skovsgaard T, Mir LM. Enhancement of cytotoxicity by electropermeabilization: an improved method for screening drugs. Anticancer Drugs 1998; 9: 319-25.
Glass LF, Pepine ML, Fenske NA, Jaroszeski M, Reintgen DS, Heller R. Bleomycin-mediated electrochemotherapy of metastatic melanoma. Arch Dermatol 1996; 132: 1353-7.
Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z. Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. Clin Cancer Res 2000; 6: 863-7.
Mir LM, Tounekti O, Orlowski S. Bleomycin: revival of an old drug. Gen Pharmacol 1996; 27: 745-8.
Rudolf Z, Stabuc B, Cemazar M, et al. Electrochemotherapy with bleomycin. The firms clinical experience in malignant melanoma patients. Radiol Oncol 1995; 29: 229-35.
Lluis M, Gehl J, Sersa G, et al. Standard operating procedures of the electrochemotherapy: instructions for the use of bleomycin or cisplatin administered either systemically or locally and electric pulses delivered by the Cliniporator by means of invasive or non-invasive electrodes. EJC Supplements 2006; 4: 14-25.
Kis E, Oláh J, Ócsai H, Baltas E, Gyulai R, Kemény L, Horvath AR. Electrochemotherapy of cutaneous metastases of melanoma – a case series study and systematic review of the evidence. Dermatol Surg. 2011; 37: 1-9.
Gaudy C, Richard MA, Folchetti G, Bonerandi JJ, Grob JJ. Randomized controlled study of electrochemotherapy in the local treatment of skin metastases of melanoma. J Cutan Med Surg 2006; 10: 115-21.
Ricotti E, Giuliodori K, Cataldi I, Campanati A, Ganzetti G, Ricotti G, Offidani A. Electrochemotherapy: an effective local treatment of cutaneous and subcutaneous melanoma metastases. Dermatologic Therapy 2014; 27: 148-52.
Scarlatos I, Kyrgias G, Mosa E, et al. Electrochemotherapy in cancer patients: first clinical trial in Greece. In Vivo 2011; 25: 265-74.
Caraco C, Mozzillo N, Marone U et al. Long-lasting response to electrochemotherapy in melanoma patients with cutaneous metastasis. BMC Cancer. 2013; 13:564
Campana LG, Valpione S, Mocellin S, Sundararajan R, Granziera E,
Sartore L, Chiarion-Sileni V, Rossi CR. Electrochemotherapy for disseminated superficial metastases from malignant melanoma. Br J Surg 2012; 99: 821-30.
Quaglino P, Mortera C, Osella-Abate S, Barberis M, Illengo M, Rissone M, Savoia P, Bernengo MG. Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol 2008; 15: 2215-22.
Solari N, Spagnolo F, Ponte E, Quaglia A, Lillini R, Battista M, Queirolo P, Cafiero F. Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: a series of 39 patient treated with palliative intent. J Surg Oncol 2014; 19: 270-4.
Kunte C, Letule V, Gehl J, et al. Electrochemmotherapy in the treatment of metastatic malignant melanoma: A prospective cohort study by InspECT. Br J Dermatol 2017; 176: 1475-85.
Spratt DE, Gordon Spratt EA, Wu S, DeRosa A, Lee NY, Lacouture ME, Barker CA. Efficiency of skin-directed therapy for cutaneous metastases from advanced cancer: a meta-analysis. J Clin Oncol 2014; 32: 3144-55.
Sersa G, Miklavcic D, Cemazar M, et al. Electrochemotherapy in treatment of tumours. Eur J Surg Oncol 2008; 34: 232-240.
Moller M, Salwa S, Soden D, et al. Electrochemotherapy as an adjunct or alternative to other treatments for unresectable or in-transit melanoma. Expert Rev Anticancer Ther 2009; 9: 1611-30.
Gehl J. Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003; 177: 437-47.
Snoj M, Cemazar M, Slekovac Kolar B, et al. Effective treatment of multiple unresectable skin melanoma metastases by electrochemotherapy. Croat Med J 2007; 48: 391-5.
Mir LM, Orlowski S, Belehradek J, et al. Electrochemotherapy potentiation of antitumour effect of bleomycin by local electric pulses. Eur J Cancer 1991; 27: 68-72.
Jaroszeski MJ, Dang V, Pottinger C, Hickey J, Gilbert R, Heller R. Toxicity of anticancer agents mediated by electroporation in vitro. Anticancer Drugs 2000; 11: 201-8.
Sersa G, Cemazar M, Parkins CS, Chaplin DJ. Tumour blood flow changes induced by application of electric pulses. Eur J Cancer 1999; 35: 672-7.
Jarm T, Cemazar M, Miklavcic D, et al. Antivascular effects of electrochemotherapy: implications in treatment of bleeding metastases. Expert Rev Anticancer Ther 2010; 10: 729-46.
Cemazar M, Parkins CS, Holder AL, Chaplin DJ, Tozer GM, Sersa G. Electroporation of human microvascular endothelial cells: evidence for an anti-vascular mechanism of electrochemotherapy. Br J Cancer 2001; 84: 565-70.
Markelc B, Sersa G, Cemazar M. Differential Mechanisms Associated with Vascular Disrupting Action of Electrochemotherapy: Intravital Microscopy on the Level of Single Normal and Tumor Blood Vessels. PLoS One 2013; 8: 1-11.
Orlowski S, An D, Belehradek J, et al. Antimetastatic effects of electrochemotherapy and of histoincompatible interleukin-2-secreting cells in the murine Lewis lung tumor. Anticancer Drugs 1998; 9: 551-6.
Serša G, Miklavcic D, Cemazara M, Belehradek J, Jarm T, Mir LM. Electrochemotherapy with CDDP on LPB sarcoma: Comparison of the anti-tumor effectiveness in immunocompetent and immunodeficient mice. Bioelectrochemistry and Bioenergetics 1997; 43: 279-83.
Nilsson E, von Euler H, Berendson J, et al. Electrochemical treatment of tumours. Bioelectrochemistry 2000; 51: 1-11.
Turler A, Schaefer H, Schaefer N, Wagner M, Maintz D, Qiao JC, Hoelscher AH. Experimental low-level direct current therapy in liver metastases: influence of polarity and current dose. Bioelectromagnetics 2000; 21: 395-401.
Brizio M, Fava P, Astrua C, Cavaliere G, Savoia P. Complete regression of melanoma skin metastases after electrochemotherapy plus ipilimumab treatment: an unusual clinical presentation. Eur
J Dermatol 2015; 25: 271-2.
Mozzillo N, Simeone E, Benedetto L, Curvietto M, Giannarelli D, Gentilcore G, et al. Assessing a novel immuno-oncology-based combination therapy: ipilimumab plus electrochemotherapy. Oncoimmunology 2015; 4: e1008842.
Mir-Bonafe JM, Vilalta A, Alarcon I, et al. Electrochemotherapy in the Treatment of Melanoma Skin Metastases: a report on 31 cases. Actas Dermosifiliogr 2015; 106: 285-291.
Kreuter A, van Eijk T, Lehmann P, et al. Electrochemotherapy in advanced skin tumors and cutaneous metastases – a retrospective multicenter analysis. J Dtsch Dermatol Ges 2015; 13: 308-15.
Campana LG, Mocellin S, Basso M, et al. Bleomycin-based electrochemotherapy: clinical outcome from a single institution’s experience with 52 patients. Ann Surg Oncol 2009; 16: 191-9.
Quick links
© 2018 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe